세계의 혈액 스크리닝 시장 : 제품 및 서비스, 기술, 최종 사용자별 예측(2025-2030년)

The Blood Screening Market was valued at USD 4.90 billion in 2023, expected to reach USD 5.31 billion in 2024, and is projected to grow at a CAGR of 8.74%, to USD 8.82 billion by 2030.

Blood screening is a critical diagnostic process designed to ensure blood safety by detecting infectious diseases, pathogens, and other irregularities. This process is essential for both blood donations and medical diagnostics, aiming to prevent transfusion-transmitted infections and contribute to early detection of diseases such as HIV, hepatitis, and syphilis. Applications of blood screening span across diverse end-use settings including hospitals, blood banks, and diagnostic laboratories, offering significant benefits in terms of disease surveillance and public health protection. Enhanced global awareness on health and safety, coupled with growing demand for early disease detection, are major growth drivers. Advances in technology, like next-gen sequencing and molecular diagnostics, offer promising potential for market expansion. Innovations in automation and AI present opportunities to enhance screening accuracy and efficiency, addressing challenges like error rates and process time. However, the market faces limitations such as high costs associated with advanced screening technologies and stringent regulatory landscapes that can slow down innovation. End-users in low-to-middle income countries often struggle with cost-prohibitive screening methods, highlighting an ongoing challenge. Additionally, the complexity of pathogen mutation rates necessitates ongoing research and development to maintain screening efficacy. To capitalize on emerging opportunities, companies should invest in cost-effective, rapid testing methods, potentially through partnerships with tech firms to advance AI-driven diagnostics. Research into multiplex testing, enabling simultaneous detection of multiple pathogens, could revolutionize screening efficiency and safety. Continuous education on the importance of blood screening and government support through favorable policies could further catalyze market growth. A proactive approach combining these strategies could help overcome current market obstacles while aligning with the increasing demand for comprehensive health safety solutions, thus facilitating significant business growth in the blood screening market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Blood Screening Market

The Blood Screening Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing demand for donated blood and rising number of blood donations
  • Rising prevalence of infectious diseases and the emergence of newer pathogens
  • Increase in affordability and adoption of nucleic acid test for blood screening
• Market Restraints
  • High price for blood screening diagnostics
• Market Opportunities
  • Technological Advancements in blood screening devices
  • Improved POC diagnostics for blood screening
• Market Challenges
  • Lack of legislation, regulations, and policies on blood screening

Porter's Five Forces: A Strategic Tool for Navigating the Blood Screening Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Blood Screening Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Blood Screening Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Blood Screening Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Blood Screening Market

A detailed market share analysis in the Blood Screening Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Blood Screening Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Blood Screening Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Blood Screening Market

A strategic analysis of the Blood Screening Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Blood Screening Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alfa Scientific Designs, Inc., Becton, Dickinson And Company, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, bioMerieux SA, Danaher Corporation, DiaSorin S.p.A., Environmental & Scientific Instruments Co., F. Hoffmann-La Roche AG, GE HealthCare Technologies, Inc., GFE, Grifols, S.A., Immucor, Inc., Laboratory Corporation of America Holdings, Lifeloc Technologies, Inc, Omega Laboratories, Inc., OraSure Technologies, Inc., Ortho Clinical Diagnostics, Inc., PerkinElmer, Inc., PixCell Medical Technologies Ltd., Premier Biotech, Inc., Siemens Healthineers AG, Thermo Fisher Scientific Inc., and Trinity Biotech Plc.

Market Segmentation & Coverage

This research report categorizes the Blood Screening Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product & Service, market is studied across Instruments, Outright Purchase, and Reagents & Kits. The Reagents & Kits is further studied across ELISA Reagents & Kits and NAT Reagents & Kits. The ELISA Reagents & Kits is further studied across Conjugates, Controls, Immunosorbents, Sample Diluents & Wash Solutions, and Substrates. The NAT Reagents & Kits is further studied across Buffers, Nucleotides, & Solutions, Enzymes & Polymerases, Labeling & Detection Reagents, Probes & Primers, and Standards & Controls.
• Based on Technology, market is studied across ELISA, NAT, NGS, Rapid Tests, and Western Blot Assays. The ELISA is further studied across Chemiluminescent Immunoassay, Colorimetric Immunoassay, and Fluorescent immunoassay. The NAT is further studied across Real-Time Polymerase Chain Reaction and Transcription-Mediated Amplification.
• Based on End-User, market is studied across Blood Banks and Hospitals.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing demand for donated blood and rising number of blood donations
    • 5.1.1.2. Rising prevalence of infectious diseases and the emergence of newer pathogens
    • 5.1.1.3. Increase in affordability and adoption of nucleic acid test for blood screening
  • 5.1.2. Restraints
    • 5.1.2.1. High price for blood screening diagnostics
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological Advancements in blood screening devices
    • 5.1.3.2. Improved POC diagnostics for blood screening
  • 5.1.4. Challenges
    • 5.1.4.1. Lack of legislation, regulations, and policies on blood screening
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Rising adoption of instruments and consumables for conducting accurate tests
  • 5.2.2. Technology: Development of enzyme-linked immunosorbent assay and mass spectrometry technology
  • 5.2.3. Application: Significant applications of infectious disease and cancer screening to prevent the spread of infections
  • 5.2.4. End-User: Increasing use of blood screening in hospitals and laboratories
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Blood Screening Market, by Product & Service

• 6.1. Introduction
• 6.2. Instruments
• 6.3. Outright Purchase
• 6.4. Reagents & Kits
  • 6.4.1. ELISA Reagents & Kits
    • 6.4.1.1. Conjugates
    • 6.4.1.2. Controls
    • 6.4.1.3. Immunosorbents
    • 6.4.1.4. Sample Diluents & Wash Solutions
    • 6.4.1.5. Substrates
  • 6.4.2. NAT Reagents & Kits
    • 6.4.2.1. Buffers, Nucleotides, & Solutions
    • 6.4.2.2. Enzymes & Polymerases
    • 6.4.2.3. Labeling & Detection Reagents
    • 6.4.2.4. Probes & Primers
    • 6.4.2.5. Standards & Controls

7. Blood Screening Market, by Technology

• 7.1. Introduction
• 7.2. ELISA
  • 7.2.1. Chemiluminescent Immunoassay
  • 7.2.2. Colorimetric Immunoassay
  • 7.2.3. Fluorescent immunoassay
• 7.3. NAT
  • 7.3.1. Real-Time Polymerase Chain Reaction
  • 7.3.2. Transcription-Mediated Amplification
• 7.4. NGS
• 7.5. Rapid Tests
• 7.6. Western Blot Assays

8. Blood Screening Market, by End-User

• 8.1. Introduction
• 8.2. Blood Banks
• 8.3. Hospitals

9. Americas Blood Screening Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Blood Screening Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Blood Screening Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Harbinger Health Raises $140M to Study Blood-Based Cancer Screening Test
  • 12.3.2. Oxford Biodynamics Announces US Launch of its 94% Accurate EpiSwitch Prostate Screening Blood Test to Men With Prostate Cancer Risk
  • 12.3.3. Walgreens and Freenome to Advance Blood-Based Test Trials For Cancer
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Alfa Scientific Designs, Inc.
• 3. Becton, Dickinson And Company
• 4. Bio-Rad Laboratories, Inc.
• 5. Bio-Techne Corporation
• 6. bioMerieux SA
• 7. Danaher Corporation
• 8. DiaSorin S.p.A.
• 9. Environmental & Scientific Instruments Co.
• 10. F. Hoffmann-La Roche AG
• 11. GE HealthCare Technologies, Inc.
• 12. GFE
• 13. Grifols, S.A.
• 14. Immucor, Inc.
• 15. Laboratory Corporation of America Holdings
• 16. Lifeloc Technologies, Inc
• 17. Omega Laboratories, Inc.
• 18. OraSure Technologies, Inc.
• 19. Ortho Clinical Diagnostics, Inc.
• 20. PerkinElmer, Inc.
• 21. PixCell Medical Technologies Ltd.
• 22. Premier Biotech, Inc.
• 23. Siemens Healthineers AG
• 24. Thermo Fisher Scientific Inc.
• 25. Trinity Biotech Plc